Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,756 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06428422 | The Impact of Probiotic on Survival and Treatment Response in Metastatic Non-small Cell Lung Cancer Patients | recruiting | N/A | 100 | Necmettin Erbakan UniversityOTHER | 1 | Aug 16, 2024 | clinicaltrials |
| NCT06532149 | ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer(EROS) | recruiting | — | 80 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 |
| Aug 9, 2024 |
| clinicaltrials |
| NCT06534489 | Surgical Strategy of NSCLC Patients After Neo-adjuvant or Induction Treatment | recruiting | — | 50 | Ruijin HospitalOTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT06534762 | Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study | recruiting | Phase 2 | 260 | Zhejiang Provincial People's HospitalOTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT06528847 | Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung Adenocarcinoma | recruiting | Phase 2 | 62 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06394674 | High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib | recruiting | Phase 2 | 84 | Changhai HospitalOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT06492421 | Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer. | recruiting | Phase 2 | 90 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT06476093 | SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer | recruiting | N/A | 46 | The First People's Hospital of LianyungangOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT03198546 | GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT03769129 | Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC | recruiting | N/A | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT03778814 | TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors | recruiting | Phase 1 | 30 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05060796 | Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC | recruiting | Early Phase 1 | 11 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05532696 | Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients | recruiting | Phase 1 / Phase 2 | 61 | Anbogen Therapeutics, Inc.INDUSTRY | 1 | Jun 24, 2024 | clinicaltrials |
| NCT05284539 | Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer(Awesome) | recruiting | Phase 2 | 760 | Hunan Province Tumor HospitalOTHER | 1 | Jun 7, 2024 | clinicaltrials |
| NCT06445881 | Efficacy and Safety of Modified Si Jun Zi Tang in Perioperative NSCLC Treatment(MSJZT-NSCLC) | recruiting | Phase 2 | 60 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT04322617 | Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer(ATHENA) | recruiting | Phase 2 / Phase 3 | 1,200 | Hunan Province Tumor HospitalOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05059951 | Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer(CREATE) | recruiting | — | 15,000 | Hunan Province Tumor HospitalOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT06440954 | Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases(EPIC) | recruiting | Phase 2 | 220 | Hunan Province Tumor HospitalOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05717803 | Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012) | recruiting | Phase 3 | 307 | Fudan UniversityOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT05266846 | Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK(BEYOND) | recruiting | Phase 2 | 78 | Hunan Province Tumor HospitalOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT05584267 | Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy | recruiting | Phase 2 | 140 | Hunan Province Tumor HospitalOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT06109558 | The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC(PROFILE) | recruiting | Phase 1 / Phase 2 | 120 | Hunan Province Tumor HospitalOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT04865250 | Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC(iReP) | recruiting | Phase 2 | 20 | University Hospital HeidelbergOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT05525338 | Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels(ADAPT ALEC) | recruiting | Phase 4 | 196 | University Medical Center GroningenOTHER | 2 | May 13, 2024 | clinicaltrials |
| NCT06109454 | Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After Radical Surgery | recruiting | — | 240 | Liaoning Cancer Hospital & InstituteOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT04680377 | Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients(Microdurva) | recruiting | — | 44 | Jun Zhang, MD, PhDOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06403735 | A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 250 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2024 | clinicaltrials |
| NCT06404164 | Pulmonary Watershed Topographic Map Navigation for Lung Nodule Resection | recruiting | N/A | 3,000 | Guangdong Provincial People's HospitalOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06300177 | D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure | recruiting | Phase 3 | 522 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT06369181 | Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC | recruiting | — | 50 | Fudan UniversityOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT06169956 | An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany(NENI) | recruiting | — | 400 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 18, 2024 | clinicaltrials |
| NCT02889666 | A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer(CCODG-NSCLC) | recruiting | Phase 1 | 500 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06363734 | Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial | recruiting | Phase 2 | 32 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT06361784 | Improving the Success Rate for Thoracic Radiotherapy Through Specific Cardiac Substructure Dosimetry: Location Matters. (LOCATION MATTERS)(LM) | recruiting | — | 150 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT06361589 | Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients | recruiting | — | 200 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06225804 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer | recruiting | Phase 1 | 164 | Abbisko Therapeutics Co, LtdINDUSTRY | 2 | Mar 18, 2024 | clinicaltrials |
| NCT06020430 | Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy | recruiting | N/A | 134 | Hubei Cancer HospitalOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06037733 | Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy | recruiting | N/A | 134 | Hubei Cancer HospitalOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06053099 | A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19)(ROSIE) | recruiting | N/A | 300 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT05332925 | Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC(TUMORIN) | recruiting | — | 25 | Jun Zhang, MD, PhDOTHER | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05377658 | AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer | recruiting | Phase 2 | 43 | Henan Cancer HospitalOTHER_GOV | 1 | Feb 21, 2024 | clinicaltrials |
| NCT05965024 | Exploration on the Value of MRD Based on ctDNA Detection in Predicting Recurrence of Resected Non-small Cell Lung Cancer | recruiting | — | 377 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT06255197 | Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers | recruiting | — | 60,000 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT06241807 | Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC | recruiting | Phase 2 | 30 | Shandong Cancer Hospital and InstituteOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT04282044 | Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | recruiting | Phase 1 | 60 | BioEclipse TherapeuticsINDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05382728 | Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO) | recruiting | Phase 3 | 680 | TYK Medicines, IncINDUSTRY | 1 | Jan 30, 2024 | clinicaltrials |
| NCT05011487 | Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC(NOCE01) | recruiting | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT06198868 | MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC | recruiting | — | 60 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Jan 12, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Aug 16, 2024source: clinicaltrials